Compare Bristol-Myers Squibb Co (BMY) vs JPMorgan Diversified Return International Eqty ETF (JPIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs JPMorgan Diversified Return International Eqty ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.62 (market cap $116.30B), while JPMorgan Diversified Return International Eqty ETF trades at $73.33. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while JPMorgan Diversified Return International Eqty ETF pays none. Which is the better fit depends on your goals.
| BMY | JPIN | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | — |
52-Week High | $62.37 | $76.96 |
52-Week Low | $42.60 | $63.14 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
JPIN trades at $72.785, down 0.78% on the day, with technical indicators showing a neutral to bearish bias. The stock faces resistance near $73 and support at $72. Recent corporate actions include a declared dividend of $0.91 scheduled for June 2026. Market sentiment remains mixed, with oscillators neutral and moving averages signaling bearish pressure.
The outlook for JPIN is cautious due to weak technical momentum and limited fundamental data availability. Key risks include market volatility and reliance on international equity performance. Investors should monitor upcoming financial disclosures for clarity on valuation and profitability metrics to assess long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →
